Introduction: The study aimed to investigate the diagnostic utility of diffusion-weighted MRI (DW-MRI) in differentiating residual bladder cancer from benign postoperative changes before a second transurethral resection of the bladder (TURB). Materials and Methods: Of the 75 bladder cancer patients who underwent a second TURB from 2013 to 2015, 23 patients who underwent multi-sequence bladder MRI after their initial TURB were retrospectively evaluated. Thirty lesions were histologically examined at the second TURB and the results of them were compared with the findings obtained through T2-weighted MRI, dynamic contrast-enhanced MRI (DCE-MRI), and DW-MRI. Results: Positive findings of 27, 28, and 15 lesions showed up on T2W-, DCE-, and DW-MRI, respectively. Thirteen lesions were confirmed histologically to constitute residual cancer. The sensitivity/specificity/accuracy of T2W-, DCE-, and DW-MRI were 100/18/53, 100/12/50, and 92/82/87%, respectively. DW-MRI was significantly superior in specificity and accuracy to T2W- (p < 0.01 for both) and DCE-MRI (p < 0.01 for both). Conclusions: This study first showed the superiority of DW-MRI to T2W- and DCE-MRI in differentiating residual cancer before a second TURB.

Keywords:
Postoperative period, Transurethral resection, Urinary bladder neoplasms, Diffusion magnetic resonance imaging, Magnetic resonance imaging
1.
Babjuk M, Böhle A, Burger M, Capoun O, Cohen D, Compérat EM, Hernández V, Kaasinen E, Palou J, Rouprêt M, van Rhijn BW, Shariat SF, Soukup V, Sylvester RJ, Zigeuner R: EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016. Eur Urol 2017;71:447-461.
2.
Chang SS, Boorjian SA, Chou R, Clark PE, Daneshmand S, Konety BR, Pruthi R, Quale DZ, Ritch CR, Seigne JD, Skinner EC, Smith ND, McKiernan JM: Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline. J Urol 2016;196:1021-1029.
3.
McKibben MJ, Woods ME: Preoperative imaging for staging bladder cancer. Curr Urol Rep 2015;16:22.
4.
Dobson MJ, Carrington BM, Collins CD, Ryder WD, Read G, Hutchinson CE, Hawnaur JM: The assessment of irradiated bladder carcinoma using dynamic contrast-enhanced MR imaging. Clin Radiol 2001;56:94-98.
5.
Johnson RJ, Carrington BM, Jenkins JP, Barnard RJ, Read G, Isherwood I: Accuracy in staging carcinoma of the bladder by magnetic resonance imaging. Clin Radiol 1990;41:258-263.
6.
Koh DM, Collins DJ: Diffusion-weighted MRI in the body: applications and challenges in oncology. AJR Am J Roentgenol 2007;188:1622-1635.
7.
Padhani AR, Liu G, Koh DM, Chenevert TL, Thoeny HC, Takahara T, Dzik-Jurasz A, Ross BD, Van Cauteren M, Collins D, Hammoud DA, Rustin GJ, Taouli B, Choyke PL: Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia 2009;11:102-125.
8.
Yoshida S, Koga F, Masuda H, Fujii Y, Kihara K: Role of diffusion-weighted magnetic resonance imaging as an imaging biomarker of urothelial carcinoma. Int J Urol 2014;21:1190-1200.
9.
Takeuchi M, Sasaki S, Naiki T, Kawai N, Kohri K, Hara M, Shibamoto Y: MR imaging of urinary bladder cancer for T-staging: a review and a pictorial essay of diffusion-weighted imaging. J Magn Reson Imaging 2013;38:1299-1309.
10.
Avcu S, Koseoglu MN, Ceylan K, Bulut MD, Dbulutand M, Unal O: The value of diffusion-weighted MRI in the diagnosis of malignant and benign urinary bladder lesions. Br J Radiol 2011;84:875-882.
11.
Dağgülli M, Onur MR, Fırdolaş F, Onur R, Kocakoç E, Orhan İ: Role of diffusion MRI and apparent diffusion coefficient measurement in the diagnosis, staging and pathological classification of bladder tumors. Urol Int 2011;87:346-352.
12.
El-Assmy A, Abou-El-Ghar ME, Mosbah A, El-Nahas AR, Refaie HF, Hekal IA, El-Diasty T, Ibrahiem el H: Bladder tumour staging: comparison of diffusion- and T2-weighted MR imaging. Eur Radiol 2009;19:1575-1581.
13.
Kobayashi S, Koga F, Yoshida S, Masuda H, Ishii C, Tanaka H, Komai Y, Yokoyama M, Saito K, Fujii Y, Kawakami S, Kihara K: Diagnostic performance of diffusion-weighted magnetic resonance imaging in bladder cancer: potential utility of apparent diffusion coefficient values as a biomarker to predict clinical aggressiveness. Eur Radiol 2011;21:2178-2186.
14.
Matsuki M, Inada Y, Tatsugami F, Tanikake M, Narabayashi I, Katsuoka Y: Diffusion-weighted MR imaging for urinary bladder carcinoma: initial results. Eur Radiol 2007;17:201-204.
15.
Abou-El-Ghar ME, El-Assmy A, Refaie HF, El-Diasty T: Bladder cancer: diagnosis with diffusion-weighted MR imaging in patients with gross hematuria. Radiology 2009;251:415-421.
16.
El-Assmy A, Abou-El-Ghar ME, Refaie HF, Mosbah A, El-Diasty T: Diffusion-weighted magnetic resonance imaging in follow-up of superficial urinary bladder carcinoma after transurethral resection: initial experience. BJU Int 2012;110(11 pt B):E622-E627.
17.
Wang HJ, Pui MH, Guo Y, Yang D, Pan BT, Zhou XH: Diffusion-weighted MRI in bladder carcinoma: the differentiation between tumor recurrence and benign changes after resection. Abdom Imaging 2014;39:135-141.
18.
Mostofi FK, Sobin LH, Torloni H: Histological Typing of Urinary Bladder Tumours. Geneva, World Health Organization, 1973.
19.
Sobin LH, Gospodarowicz MK, Wittekind C; International Union against Cancer, ebrary Inc.: TNM Classification of Malignant Tumours. Chichester, West Sussex, Hoboken, Wiley-Blackwell, 2009.
20.
Yoshida S, Koga F, Kawakami S, Ishii C, Tanaka H, Numao N, Sakai Y, Saito K, Masuda H, Fujii Y, Kihara K: Initial experience of diffusion-weighted magnetic resonance imaging to assess therapeutic response to induction chemoradiotherapy against muscle-invasive bladder cancer. Urology 2010;75:387-391.
21.
Herr HW, Donat SM: Quality control in transurethral resection of bladder tumours. BJU Int 2008;102(9 pt B):1242-1246.
22.
Yoshida S, Koga F, Kobayashi S, Ishii C, Tanaka H, Tanaka H, Komai Y, Saito K, Masuda H, Fujii Y, Kawakami S, Kihara K: Role of diffusion-weighted magnetic resonance imaging in predicting sensitivity to chemoradiotherapy in muscle-invasive bladder cancer. Int J Radiat Oncol Biol Phys 2012;83:e21-e27.
23.
Yoshida S, Koga F, Kobayashi S, Tanaka H, Satoh S, Fujii Y, Kihara K: Diffusion-weighted magnetic resonance imaging in management of bladder cancer, particularly with multimodal bladder-sparing strategy. World J Radiol 2014;6:344-354.
24.
Takeuchi M, Sasaki S, Ito M, Okada S, Takahashi S, Kawai T, Suzuki K, Oshima H, Hara M, Shibamoto Y: Urinary bladder cancer: diffusion-weighted MR imaging-accuracy for diagnosing T stage and estimating histologic grade. Radiology 2009;251:112-121.
25.
Watanabe H, Kanematsu M, Kondo H, Goshima S, Tsuge Y, Onozuka M, Moriyama N: Preoperative T staging of urinary bladder cancer: does diffusion-weighted MRI have supplementary value? AJR Am J Roentgenol 2009;192:1361-1366.
26.
Kobayashi S, Koga F, Kajino K, Yoshita S, Ishii C, Tanaka H, Saito K, Masuda H, Fujii Y, Yamada T, Kihara K: Apparent diffusion coefficient value reflects invasive and proliferative potential of bladder cancer. J Magn Reson Imaging 2014;39:172-178.
27.
Donaldson SB, Bonington SC, Kershaw LE, Cowan R, Lyons J, Elliott T, Carrington BM: Dynamic contrast-enhanced MRI in patients with muscle-invasive transitional cell carcinoma of the bladder can distinguish between residual tumour and post-chemotherapy effect. Eur J Radiol 2013;82:2161-2168.
28.
Lin WC, Chen JH: Pitfalls and limitations of diffusion-weighted magnetic resonance imaging in the diagnosis of urinary bladder cancer. Transl Oncol 2015;8:217-230.
29.
Koh DM, Blackledge M, Padhani AR, Takahara T, Kwee TC, Leach MO, Collins DJ: Whole-body diffusion-weighted MRI: tips, tricks, and pitfalls. AJR Am J Roentgenol 2012;199:252-262.
30.
Yoshida S, Fujii Y, Yokoyama M, Ishii C, Saito K, Koga F, Masuda H, Kobayashi T, Kawakami S, Kihara K: Female urethral diverticular abscess clearly depicted by diffusion-weighted magnetic resonance imaging. Int J Urol 2008;15:460-461.
31.
Oto A, Zhu F, Kulkarni K, Karczmar GS, Turner JR, Rubin D: Evaluation of diffusion-weighted MR imaging for detection of bowel inflammation in patients with Crohn's disease. Acad Radiol 2009;16:597-603.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.